Qihan Biotech, a Chinese gene-editing technology developer, has received $25.5 million in Series A+ funding round.
Led by CMB International Capital Corp. Ltd., previous backers including Sequoia Capital China and Northern Light Venture Capital, as well as BC Capital and Legend Star also joined the round.
Qihan Biotech plans to use the money raised from the funding, which has brought its total Series A funding raised so far to $33.3 million, for the preclinical research and development of Xenotransplantation.
The company said that it is also planning to explore the potential application of gene-editing technology in medical treatment and other fields.